SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (13844)1/28/1998 7:23:00 PM
From: Proton  Read Replies (1) | Respond to of 32384
 
Re: Relative Performance

LGND relative performance update: to BTK, -7.7%; to DRG, -17.7%.

I shan't post these every day, but they're significant enough that we
must see them.

I looked at relative performance from 1/1/97 to date and from 1/1/96
to date (a longer-term look).

Here are the performance figures:

1996-date 1997-date
DRG +97.3% +62.5%
BTK +20.7% +11.9%
LGND +9.9% -20.6%

LGND has been a challenging member of an historically challenging
group. I think your remarks about earnings driving wealth-building
share growth are well taken, Andreas.

Pý



To: Andreas Helke who wrote (13844)1/29/1998 12:55:00 AM
From: Henry Niman  Respond to of 32384
 
Andrea, I found a Biotech review with picks for 1998:

buyside.com

David Malowa of Bear Stearns likes LGND and has a 12 month target of 18-20 (which would be about 6 months from now). In general, the article indicated that 1997 was as successful as hoped, the industry was still maturing, and one of the main price drivers was NDA filings.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News